|
0
|
|
Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.
(academic.oup.com)
|
Havens JP
…
Bares SH
Clinical Infectious Diseases
2026-09-01
|
#hiv
#pharmacoeconomics
#implementation
|
|
0
|
|
Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial.
(academic.oup.com)
|
Chen NY
…
Cheng CY
Clinical Infectious Diseases
2026-09-01
|
#hiv
#viremia
#adherence
#suppression
|
|
0
|
|
Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.
(nature.com)
|
Tan TS
…
Lichterfeld M
Nature Immunology
2026-09-01
|
#hiv
#immunity
#reservoir
#nk cells
|
|
0
|
|
Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.
(academic.oup.com)
|
Ferreira-Tata C
…
Rivero A
Open Forum Infectious Diseases
2026-09-01
|
#measles
#immunity
#serology
#vaccination
#hiv
|
|
0
|
|
Bronchoalveolar Lavage Fluid Lipoarabinomannan as a Rapid Rule-Out Tool for Smear-Negative Pulmonary Tuberculosis in a Nonhuman Immunodeficiency Virus-Predominant, High-Burden Setting: A Prospective Study.
(academic.oup.com)
|
Youburee W
…
Rotjanapan P
Open Forum Infectious Diseases
2026-09-01
|
#tb
#diagnostics
#biomarker
#bronchoscopy
#hiv
|
|
0
|
|
Clinically Relevant Risk of Hepatitis B Virus Infection and Reactivation in People With HIV After Withdrawal of Anti-HBV-Active Antiretroviral Therapy in Japan.
(academic.oup.com)
|
Adachi E
…
Yotsuyanagi H
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#hepatitis
#co-infection
#immunosuppression
|
|
0
|
|
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study.
(academic.oup.com)
|
Sempere A
…
Blanco JL
Journal of Antimicrobial Chemotherapy
2026-09-01
|
#antibiotic
#hiv
#pharmacokinetics
#treatment-switching
|
|
0
|
|
Transforming Human Immunodeficiency Virus Outcomes: Impact of a Rapid Antiretroviral Therapy Model on Linkage to Care and Viral Suppression in Memphis, Tennessee.
(academic.oup.com)
|
Pettit AC
…
Rebeiro PF
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#viral_suppression
#intervention
#treatment-outcomes
|
|
0
|
|
Population HIV Viremia and Epidemic Transition: Findings From Sequential Surveys in 6 Sub-Saharan African Countries.
(academic.oup.com)
|
Farahani M
…
El-Sadr WM
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#epidemiology
#viremia
#treatment
#incidence
|
|
0
|
|
Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis.
(academic.oup.com)
|
Hoffman R
…
Grinspoon SK
Open Forum Infectious Diseases
2026-09-01
|
#hypertension
#hiv
#cardiovascular
#epidemiology
|
|
0
|
|
Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.
(academic.oup.com)
|
Castagna A
…
Prakash M
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#amr
#immunity
#clinical trial
|
|
0
|
|
HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy.
(academic.oup.com)
|
Abdullahi A
…
Gupta RK
Journal of Antimicrobial Chemotherapy
2026-09-01
|
#amr
#hiv
#sequencing
#integrase
|
|
0
|
|
Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics.
(academic.oup.com)
|
Christopoulos KA
…
Colasanti JA
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#adherence
#treatment
|
|
0
|
|
Integrating Cervical Cancer Prevention into HIV Services in Sub-Saharan Africa: A Narrative Review Addressing the Dual Burden Among Women.
(academic.oup.com)
|
Ceesay E
…
Belec L
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#cervical cancer
#screening
#vaccination
#co-infection
|
|
0
|
|
Changes in HIV Clinical Visit Frequency and Viral Suppression During and After COVID-19 Restrictions: A Nested Study Within NA-ACCORD in the US, 2018-2021.
(academic.oup.com)
|
Zhang Y
…
Althoff KN
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#pandemic
#viral_suppression
#cohort study
#access
|
|
0
|
|
Identifying socioeconomic characteristics of pregnant women aged 15-50 years diagnosed with HIV during pregnancy, the Netherlands, 2016 to 2023.
(eurosurveillance.org)
|
Smit C
…
van der Valk M
Eurosurveillance
2026-09-01
|
#pregnancy
#hiv
#screening
#epidemiology
#socioeconomic
|
|
0
|
|
Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017-2019.
(academic.oup.com)
|
Abdullahi A
…
Gupta RK
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#viralsuppression
#treatment
#cohort
|
|
0
|
|
Perspectives on PrEP/PEP Integration in Telehealth Gender-Affirming Care: A Survey of Clients From a National Telehealth Platform.
(academic.oup.com)
|
Aitcheson N
…
Momplaisir F
Open Forum Infectious Diseases
2026-09-01
|
#prevention
#hiv
#telehealth
#prophylaxis
#transgender
|
|
0
|
|
In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.
(nature.com)
|
Gubser C
…
Lewin SR
Nature Communications
2026-09-01
|
#immunotherapy
#hiv
#transcriptomics
#exhaustion
#immunity
|
|
0
|
|
Increasing Multimorbidity Burden After COVID-19 Infection Among People With and Without HIV in the United States: Insights From the National Clinical Cohort Collaborative (N3C).
(academic.oup.com)
|
Wang Y
…
Sun J
Open Forum Infectious Diseases
2026-09-01
|
#covid-19
#hiv
#comorbidity
#epidemiology
#cohort
|
|
0
|
|
Safety of the M72/AS01 Tuberculosis Vaccine in People Living With HIV: A Systematic Review and Meta-Analysis.
(academic.oup.com)
|
Pereira PS
…
Barreto-Duarte B
Open Forum Infectious Diseases
2026-09-01
|
#vaccination
#hiv
#tb
#meta-analysis
#immunogenicity
|
|
0
|
|
Pre-treatment HIV-1 drug resistance spectrum and molecular transmission network characteristics in Zhejiang Province, 2023: implications for targeted control of drug-resistant HIV transmission.
(academic.oup.com)
|
Fan Q
…
Chai C
Journal of Antimicrobial Chemotherapy
2026-09-01
|
#amr
#hiv
#molecular epidemiology
#transmission
#phylogenetic
|
|
0
|
|
Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study.
(academic.oup.com)
|
Cordova E
…
van Wyk J
Open Forum Infectious Diseases
2026-09-01
|
#hiv
#virologic suppression
#clinical trial
|